Drug Profile

Eltrombopag - Novartis

Alternative Names: 497115; Eltrombopag olamine; ETB-115; Promacta; Reboredo; Revolade; SB-497115; SB-497115-GR

Latest Information Update: 10 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ligand Pharmaceuticals
Developer French Innovative Leukemia Organisation; GlaxoSmithKline; Groupe Francophone des Myelodysplasies; GSK; Novartis; Technische Universitat Dresden
Class Antianaemics; Antineoplastics; Benzoates; Biphenyl compounds; Carboxylic acids; Hydrazines; Pyrazoles; Radioprotectives; Small molecules
Mechanism of Action Thrombopoietin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Aplastic anaemia; Idiopathic thrombocytopenic purpura
New Molecular Entity Yes

Marketed Aplastic anaemia; Idiopathic thrombocytopenic purpura; Thrombocytopenia
Phase III Acute radiation syndrome
Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Transplant rejection
Phase I/II Chronic myelomonocytic leukaemia

27 Jan 2025 Novartis completes phase II ESCALATE trial in Aplastic anaemia (Combination therapy, In adolescents, In children, In infants, Treatment-experienced, Treatment naive) in USA, Hong Kong, Netherlands, Portugal, Russia, Thailand, United Kingdom (PO) (NCT03025698) (EudraCT2015-003166-91)
06 Dec 2024 Novartis Pharmaceuticals completes Phase-II clinical trials in Aplastic anaemia (In children, In adolescents, In adults, In the elderly, Combination therapy, Treatment-naive) in China, Japan, South Korea and Taiwan (PO) (NCT04328727)
11 Apr 2024 University Children's Hospital Basel in collaboration with Novartis Pharmaceuticals completes a phase II iROM2 trial in Idiopathic thrombocytopenic purpura (Adjunctive treatment, Treatment-naive) in Switzerland (PO) (NCT04812483)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com